Full-Time

Site Quality Head

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$170k - $225k/yr

Albany, NY, USA

In Person

Category
Engineering Management (1)
Requirements
  • Bachelor's degree in Science, Chemical Engineering or related field
  • Minimum 10 plus years’ experience in Pharmaceutical Manufacturing, preferably with Drug Substance commercial manufacturing facility within a regulatory environment, including 5 years in a leadership role
  • Must pass a background check
  • Must pass a drug screen
  • May be required to pass Occupational Health Screening
  • Quality System remediation and transformation experience in API or Drug Product manufacturing facility
  • Strong verbal and written communication skills
  • Strong knowledge of business process needs of quality assurance
  • Ability to create and maintain strong working relationships with multiple organizations, both on-site and externally
  • Strong, effective leadership skills
  • Ability to enable and empower managers and hold them accountable for results
  • Ability to create a climate of trust and cooperation
  • Exhibits strong adherence to personal and company values
  • Ability to provide strategic leadership to the organization in terms of strategy development, and provide resources and execution of defined strategy
  • Ability to read, analyze and interpret financial reports, common scientific and technical journals and legal documents
  • Ability to respond to common inquiries or complaints from customers, regulatory agencies or members of the business community
  • Ability to effectively present information to all levels throughout the organization, government agencies, boards of directors and customers
Responsibilities
  • Provide technical, quality oversight and support to the VP of Quality Operations in making quality decisions
  • Ensures adequate manufacturing quality oversight across manufacturing and packaging operations. Responsible for all aspects of GMP compliance. This includes quality oversight from the point of material dispensing through final product dispatch for all products
  • Provide guidance and processes that would comply to global cross contamination control requirements
  • Provide oversight and direction to the QC laboratories
  • Support plant management groups on new products, changes to products, processes, and services to achieve a consistent approach to Quality Assurance and Regulatory Affairs
  • Drive robust site inspection readiness program, assess risks and provide guidance on compliant mitigation actions
  • Direct quality and compliance process improvements and goals for the site using current regulations and demonstrated best practices
  • Support effective and efficient continuous quality and cost improvement efforts
  • Ensure requirements of Curia global Quality Systems are implemented and maintained in each operation throughout the facility
  • Drive accountability for all decisions made affecting product and process quality
  • Evaluate and recommend solutions and implementation strategies for product/process issues through use of analytical, technical and leadership skills
  • Contribute to core values of Quality, Timeliness, Communication and Profitability
  • Direct and manage the Manufacturing Quality Assurance, validations and investigations
  • Direct and manage the Quality Systems function
  • Drive improvements to Quality performance metrics
  • Set and oversee data integrity standards at the site
  • Includes coordination of lot release / coordination of investigations and customer relationships
  • Provide plant management with data and information appropriate to reduce potential for regulatory action and assist in site productivity management. Keep plant management advised concerning agency, customer, and internal audit compliance commitments
  • Responsible to develop and maintain Quality budget on site

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$1.1B

Headquarters

Albany, New York

Founded

1991

Your Connections

People at Curia who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Biologics segment expansion under Steve Lavezoli accelerates high-margin pharmaceutical outsourcing revenue growth.
  • Carterra partnership positions Curia to capture Pacific Northwest biotech demand in antibody discovery services.
  • Gerald Auer's CFO appointment signals M&A activity and potential strategic initiatives enhancing shareholder value.

What critics are saying

  • Pace Life Sciences acquisition of New Jersey lab erodes Curia's analytical testing capacity and revenue.
  • Larger CDMOs like Lonza and Catalent undercut Curia on biologics capacity, stealing biotech contracts.
  • FDA scrutiny on srRNA manufacturing defects from Replicate Bioscience Phase 1 triggers potential client exodus.

What makes Curia unique

  • Pioneer in self-replicating RNA manufacturing, demonstrated through Replicate Bioscience Phase 1 clinical trial support.
  • Integrated enzymatic doggybone DNA technology via Touchlight collaboration expands mRNA manufacturing competitive advantages.
  • End-to-end CDMO services from discovery through cGMP manufacturing differentiate Curia from specialized competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Carlyle Group
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb.com
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

PPI News Agency
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.